| Literature DB >> 27123036 |
Xianghui Ma1, Bin Lv1, Pan Li1, Xiaoqing Jiang1, Qian Zhou1, Xiaoying Wang2, Xiumei Gao1.
Abstract
Naoxintong capsule (NXT) is a commercial medicinal product approved by the China Food and Drug Administration which is used in the treatment of stroke and coronary heart disease. However, the research on the composition and mechanism of NXT is still lacking. Our research aimed to identify the absorbable components, potential targets, and associated pathways of NXT with network pharmacology method. We explored the chemical compositions of NXT based on UPLC/Q-TOF-MS. Then, we used the five principles of drug absorption to identify absorbable ingredients. The databases of PharmMapper, Universal Protein, and the Molecule Annotation System were used to predict the main targets and related pathways. By the five principles of drug absorption as a judgment rule, we identified 63 compositions that could be absorbed in the blood in all 81 chemical compositions. Based on the constructed networks by the significant regulated 123 targets and 77 pathways, the main components that mediated the efficacy of NXT were organic acids, saponins, and tanshinones. Radix Astragali was the critical herbal medicine in NXT, which contained more active components than other herbs and regulated more targets and pathways. Our results showed that NXT had a therapeutic effect on heart diseases through the pattern "multiple components-multiple targets-multiple pathways."Entities:
Year: 2016 PMID: 27123036 PMCID: PMC4830706 DOI: 10.1155/2016/9468087
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Sixteen Chinese traditional medical herbs of NXT.
| Abbreviation | Medicinal herbs | Original plants | Content (g) |
|---|---|---|---|
| RA | Radix Astragali |
| 66 |
| RPR | Radix Paeoniae Rubra |
| 27 |
| RSM | Radix Salviae Miltiorrhizae |
| 27 |
| RAS | Radix Angelicae Sinensis |
| 27 |
| RCX | Rhizoma Chuanxiong |
| 27 |
| SP | Semen Persicae |
| 27 |
| FC | Flos Carthami |
| 13 |
| FK | Frankincense |
| 13 |
| MRH | Myrrha |
| 13 |
| CS | Caulis Spatholobi |
| 20 |
| RAB | Radix Achyranthis Bidentatae |
| 27 |
| RC | Ramulus Cinnamomi |
| 20 |
| RM | Ramulus Mori |
| 27 |
| PT | Pheretima |
| 27 |
| SCP | Scorpio |
| 13 |
| HRD | Hirudo |
| 27 |
Note. The content of 16 Chinese traditional medical herbs of NXT came from Chinese Pharmacopoeia 2015.
Figure 1UPLC/Q-TOF-MS analysis of NXT. (a) Chromatograms of NXT in positive ion mode. (b) Chromatograms of NXT in negative ion mode.
MS data in (+/−) ESI modes and the identification results for the constituents in NXT.
| Peak number | RT (min) | Identification | Mode | MS ( | Composition | Herbal source |
|---|---|---|---|---|---|---|
| 1 | 0.647 | Arginine | Pos/Neg | 174.2024 | C6H14N4O2 | PT |
| 2 | 0.702 | Valine | Pos | 117.1478 | C5H11NO2 | PT |
| 3 | 0.721 | Proline | Pos | 115.1331 | C5H9NO2 | PT |
| 4 | 0.776 | Malic acid | Neg | 134.0911 | C4H6O5 | RA |
| 5 | 1.053 | Citric acid | Neg | 192.1286 | C6H8O7 | RA |
| 6 | 1.201 | D-5-oxoproline | Neg | 129.1174 | C5H7NO3 | RAS |
| 7 | 1.201 | L-5-oxoproline | Neg | 129.1174 | C5H7NO3 | RAS |
| 8 | 1.275 | Succinic acid | Neg | 118.0910 | C4H6O4 | RAS, RAB, PT |
| 9 | 1.294 |
| Pos | 164.1601 | C9H8O3 | RAS |
| 10 | 1.310 | o-Phthalic acid | Pos | 166.1294 | C8H6O4 | RAS |
| 11 | 1.312 | Adenosine | Pos | 267.2403 | C10H13N5O4 | RAS, PT, RCX |
| 12 | 1.331 | Leucine | Pos | 131.1688 | C6H13NO2 | PT |
| 13 | 1.460 | Isoleucine | Pos | 131.1688 | C6H13NO2 | RAB |
| 14 | 1.589 | Gallic acida | Neg | 170.1207 | C7H6O5 | RPR |
| 15 | 2.199 | Phenylalanine | Pos | 165.1874 | C9H11NO2 | FC |
| 16 | 2.459 | Danshensu | Neg | 198.1701 | C9H10O5 | RSM |
| 17 | 2.606 | Palmitic acid | Neg | 256.3380 | C16H32O2 | RAS, FC, RA, SCP |
| 18 | 3.438 | Senkyunolide B | Neg | 204.2374 | C12H12O3 | RCX |
| 19 | 3.456 | Senkyunolide C | Neg | 204.2374 | C12H12O3 | RCX |
| 20 | 3.600 | Protocatechuic aldehyde | Neg | 138.1185 | C7H6O3 | RSM, RC |
| 21 | 3.974 | Mulberroside Aa | Neg | 568.5277 | C26H32O14 | RM |
| 22 | 4.122 | Gallicin | Neg | 184.1453 | C8H8O5 | RPR |
| 23 | 4.230 | Hydroxysafflor yellow A | Pos/Neg | 612.5364 | C27H32O16 | FC |
| 24 | 4.232 | 7-Hydroxycoumarin | Pos | 162.1457 | C9H6O3 | RM |
| 25 | 4.565 | Vanillic acid | Neg | 168.1459 | C8H8O4 | RCX, RPR |
| 26 | 4.694 | Benzoic acid | Neg | 122.1209 | C7H6O2 | RPR |
| 27 | 4.935 | Epicatechin | Neg | 290.2674 | C15H14O6 | CS |
| 28 | 5.157 | Catechin | Neg | 290.2674 | C15H14O6 | RPR |
| 29 | 5.212 | Albiflorin | Pos | 480.4653 | C23H28O11 | RPR |
| 30 | 5.730 | Quercetin-7-O-glucoside | Neg | 464.3754 | C21H20O12 | FC |
| 31 | 5.952 | Rutin | Neg | 610.5203 | C27H30O16 | RA |
| 32 | 5.970 | Calycosina | Neg | 284.2679 | C16H12O5 | RA |
| 33 | 5.988 | Calycosin-7-O-glucoside | Pos | 446.4075 | C22H22O10 | RA |
| 34 | 5.989 | Ferulic acida | Neg | 194.1815 | C10H10O4 | RA, RCX, RAS, RAB |
| 35 | 6.321 | Paeoniflorina | Pos | 480.466 | C23H28O11 | RPR |
| 36 | 6.358 | Pentagalloylglucosea | Neg | 940.68 | C41H32O26 | RPR |
| 37 | 6.413 | Kaempferol-3-O-rutinosidea | Pos/Neg | 594.5179 | C27H30O15 | FC |
| 38 | 6.654 | 3,5-Di-O-caffeoylquinic acida | Pos/Neg | 516.4573 | C25H24O12 | CS |
| 39 | 6.987 | Dicaffeoylquinic acid | Neg | 516.1275 | C25H24O12 | RCX |
| 40 | 7.042 | Z-Butylidenephthalidea | Neg | 188.2259 | C12H12O2 | RCX |
| 41 | 7.210 | Salvianolic acid A | Neg | 494.4578 | C26H22O10 | RSM |
| 42 | 7.449 | 4-Hydroxyl-3-butylphthalide | Pos | 206.2346 | C12H14O3 | RCX |
| 43 | 7.540 | Salvianolic acid B | Neg | 718.6220 | C36H30O16 | RSM |
| 44 | 7.688 | Ononin | Pos | 430.4107 | C22H22O9 | CS |
| 45 | 7.763 | Senkyunolide F | Pos | 206.1017 | C12H14O3 | RCX, RAS |
| 46 | 7.855 | Salvianolic acid E | Neg | 718.1512 | C36H30O16 | RSM |
| 47 | 8.243 | Biochanin A | Pos/Neg | 284.2689 | C16H12O5 | CS |
| 48 | 8.262 | (6aR,11aR)-3-Hydroxy-9,10-dimethoxy pterocarpan | Pos | 300.3107 | C17H16O5 | RA |
| 49 | 8.594 | N1-N5-(Z)-N10-(E)-tri-p-coumaroylspermidine | Pos | 583.2703 | C34H37N3O6 | FC |
| 50 | 8.740 | Benzoylpaeoniflorin | Pos | 584.5723 | C30H32O12 | RPR |
| 51 | 9.518 | Pratensein | Neg | 300.0679 | C16H12O6 | RA |
| 52 | 9.611 | Hydroxyl calendic acid | Neg | 294.4342 | C18H30O3 | SP |
| 53 | 9.648 |
| Pos | 244.2435 | C14H12O4 | RM |
| 54 | 10.240 | Formononetina | Pos/Neg | 268.2580 | C16H12O4 | RA |
| 55 | 10.405 | Astragaloside IV | Neg | 784.4633 | C41H68O14 | RA |
| 56 | 10.590 | Senkyunolide H | Neg | 220.2305 | C12H12O4 | RCX |
| 57 | 10.978 | Astragaloside II | Neg | 826.4701 | C43H70O15 | RA |
| 58 | 11.311 | Soyasaponin I | Neg | 942.5145 | C48H78O18 | RA |
| 59 | 11.422 | Methyl tanshinonate | Pos | 338.1087 | C20H18O5 | RSM |
| 60 | 11.588 | Carnosic acid | Neg | 332.4311 | C20H28O4 | RSM |
| 61 | 11.644 | Kaempferol-3-O-glucoside | Neg | 448.3752 | C21H20O11 | FC |
| 62 | 11.699 | Hydroxytanshinone IIA | Pos | 310.1199 | C19H18O4 | RSM |
| 63 | 11.792 | 3-Butylidene-7-hydroxyphalide | Neg | 204.2331 | C12H12O3 | RCX |
| 64 | 11.921 | Tanshinone II-B | Pos | 310.1187 | C19H18O4 | RSM |
| 65 | 12.198 | Senkyunolide A | Pos | 192.2516 | C12H16O2 | RCX |
| 66 | 12.975 | Salvianolic acid F | Neg | 314.0735 | C17H14O6 | RSM |
| 67 | 13.196 | Kumatakenin | Neg | 314.3359 | C17H14O6 | RA |
| 68 | 13.233 | 3-n-Butylphthalide | Pos | 190.2356 | C12H14O2 | RCX |
| 69 | 13.474 | (Z)-ligustilidea | Pos | 190.2109 | C12H14O2 | RAS |
| 70 | 13.483 | (E)-ligustilidea | Pos | 190.2109 | C12H14O2 | RAS |
| 71 | 13.917 | Trijuganone B | Pos | 280.1107 | C18H16O3 | RSM |
| 72 | 16.098 | Cryptotanshinonea | Neg | 296.3642 | C19H20O3 | RSM |
| 73 | 16.394 | Senkyunolide M | Pos | 278.1565 | C16H22O4 | RCX |
| 74 | 17.503 | O-Phthalic anhydride | Pos | 148.0207 | C8H4O3 | FC |
| 75 | 17.614 | Chlorogenic acida | Neg | 354.3120 | C16H18O9 | CS |
| 76 | 18.076 | Tanshinone IIA | Pos | 294.3430 | C19H18O3 | RSM |
| 77 | 18.205 | Angelicide | Pos | 380.1917 | C24H28O4 | RCX |
| 78 | 20.460 | Carthamidin | Pos | 288.2575 | C15H12O6 | FC |
| 79 | 22.078 | Linoleic acid | Neg | 280.2387 | C18H32O2 | SP |
| 80 | 22.659 | Acetyl-11-keto- | Pos/Neg | 512.7458 | C32H48O5 | FK |
| 81 | 22.881 | Oleanolic acid | Neg | 456.3652 | C30H48O3 | RSM |
“a” refers to the component has been verified by standard substance.
Absorption parameters of the components.
| Number | Compounds | MW |
|
| miLog | Results |
|---|---|---|---|---|---|---|
| 1 | Arginine | 174.204 | 6 | 7 | −3.632 |
|
| 2 | Valine | 117.15 | 3 | 3 | −1.91 | √ |
| 3 | Proline | 115.132 | 3 | 2 | −1.723 | √ |
| 4 | Malic acid | 134.087 | 5 | 3 | −1.57 | √ |
| 5 | Citric acid | 192.123 | 7 | 4 | −1.983 | √ |
| 6 | D-5-oxoproline | 129.115 | 4 | 2 | −2.402 | √ |
| 7 | L-5-oxoproline | 129.115 | 4 | 2 | −2.402 | √ |
| 8 | Succinic acid | 118.088 | 4 | 2 | −0.655 | √ |
| 9 |
| 164.160 | 3 | 2 | 1.43 | √ |
| 10 | o-Phthalic acid | 166.132 | 4 | 2 | 1.034 | √ |
| 11 | Adenosine | 267.245 | 9 | 5 | −0.854 | √ |
| 12 | Leucine | 131.175 | 3 | 3 | −1.382 | √ |
| 13 | Isoleucine | 131.175 | 3 | 3 | −1.41 | √ |
| 14 | Gallic acida | 170.120 | 5 | 4 | 0.589 | √ |
| 15 | Phenylalanine | 165.192 | 3 | 3 | −1.231 | √ |
| 16 | Danshensu | 198.174 | 5 | 4 | −0.251 | √ |
| 17 | Palmitic acid | 256.43 | 2 | 1 | 7.059 |
|
| 18 | Senkyunolide B | 204.225 | 3 | 1 | 2.81 | √ |
| 19 | Senkyunolide C | 204.225 | 3 | 1 | 2.574 | √ |
| 20 | Protocatechuic aldehyde | 138.122 | 3 | 2 | 0.759 | √ |
| 21 | Mulberroside Aa | 568.528 | 14 | 10 | −0.852 | √ |
| 22 | Gallicin | 184.147 | 5 | 3 | 0.848 | √ |
| 23 | Hydroxysafflor yellow A | 612.54 | 16 | 12 | −4.12 | √ |
| 24 | 7-Hydroxycoumarin | 162.144 | 3 | 1 | 1.511 | √ |
| 25 | Vanillic acid | 168.148 | 4 | 2 | 1.187 | √ |
| 26 | Benzoic acid | 122.123 | 2 | 1 | 1.848 | √ |
| 27 | Epicatechin | 290.271 | 6 | 5 | 1.369 | √ |
| 28 | Catechin | 290.271 | 6 | 5 | 1.369 | √ |
| 29 | Albiflorin | 480.466 | 11 | 5 | −1.636 |
|
| 30 | Quercetin-7-O-glucoside | 464.379 | 12 | 8 | −0.104 |
|
| 31 | Rutin | 610.521 | 16 | 10 | −1.063 | √ |
| 32 | Calycosina | 284.267 | 5 | 2 | 2.377 | √ |
| 33 | Calycosin-7-O-glucoside | 446.408 | 10 | 5 | 0.59 | √ |
| 34 | Ferulic acida | 194.186 | 4 | 2 | 1.249 | √ |
| 35 | Paeoniflorina | 480.466 | 11 | 5 | 0.044 |
|
| 36 | Pentagalloylglucosea | 940.681 | 26 | 15 | 2.761 | √ |
| 37 | Kaempferol-3-O-rutinosidea | 594.522 | 15 | 9 | −0.574 | √ |
| 38 | 3,5-Di-O-caffeoylquinic acida | 516.455 | 12 | 7 | 1.424 |
|
| 39 | Dicaffeoylquinic acid | 516.46 | 12 | 7 | 1.21 |
|
| 40 | Z-Butylidenephthalidea | 188.226 | 2 | 0 | 3.077 | √ |
| 41 | Salvianolic acid A | 494.452 | 10 | 7 | 3.014 |
|
| 42 | 4-Hydroxyl-3-butylphthalide | 206.241 | 3 | 1 | 3.42 | √ |
| 43 | Salvianolic acid B | 718.620 | 16 | 9 | 1.615 |
|
| 44 | Ononin | 430.409 | 9 | 4 | 1.307 | √ |
| 45 | Senkyunolide F | 206.24 | 3 | 1 | 1.72 | √ |
| 46 | Salvianolic acid E | 718.62 | 16 | 10 | 2.83 |
|
| 47 | Biochanin A | 284.267 | 5 | 2 | 2.804 | √ |
| 48 | (6aR,11aR)-3-Hydroxy-9,10-dimethoxy pterocarpan | 300.31 | 5 | 1 | 2.546 | √ |
| 49 | N1-N5-(Z)-N10-(E)-tri-p-coumaroylspermidine | 538.68 | 9 | 5 | 4.3 |
|
| 50 | Benzoylpaeoniflorin | 584.574 | 12 | 4 | 2.472 |
|
| 51 | Pratensein | 300.27 | 6 | 3 | 2.09 | √ |
| 52 | Hydroxyl calendic acid | 294.435 | 3 | 2 | 4.93 | √ |
| 53 | Trans-Oxyresveratrol | 244.246 | 4 | 4 | 2.723 | √ |
| 54 | Formononetina | 268.268 | 4 | 1 | 3.095 | √ |
| 55 | Astragaloside IV | 784.98 | 14 | 9 | 1.21 | √ |
| 56 | Senkyunolide H | 220.224 | 4 | 2 | 2.314 | √ |
| 57 | Astragaloside II | 827.02 | 15 | 8 | 1.91 | √ |
| 58 | Soyasaponin I | 943.13 | 18 | 11 | 1.7 |
|
| 59 | Methyl tanshinonate | 338.36 | 5 | 0 | 0.93 | √ |
| 60 | Carnosic acid | 332.440 | 4 | 3 | 4.603 | √ |
| 61 | Kaempferol-3-O-glucoside | 448.380 | 11 | 7 | 0.125 |
|
| 62 | Hydroxytanshinone IIA | 310.35 | 4 | 1 | 3.24 | √ |
| 63 | 3-Butylidene-7-hydroxyphthalide | 204.225 | 3 | 1 | 2.81 | √ |
| 64 | Tanshinone II-B | 310.35 | 4 | 1 | 2.97 | √ |
| 65 | Senkyunolide A | 192.258 | 2 | 0 | 3.521 | √ |
| 66 | Salvianolic acid F | 314.29 | 6 | 5 | 2.33 | √ |
| 67 | Kumatakenin | 314.29 | 6 | 2 | 2.98 | √ |
| 68 | 3-n-Butylphthalide | 190.242 | 2 | 0 | 3.483 | √ |
| 69 | (Z)-Ligustilidea | 190.242 | 2 | 0 | 2.927 | √ |
| 70 | (E)-Ligustilidea | 190.242 | 2 | 0 | 2.927 | √ |
| 71 | Trijuganone B | 280.32 | 3 | 1 | 3.9 | √ |
| 72 | Cryptotanshinonea | 296.366 | 3 | 0 | 3.83 | √ |
| 73 | Senkyunolide M | 278.35 | 4 | 1 | 2.55 | √ |
| 74 | O-Phthalic anhydride | 148.12 | 3 | 0 | 0.93 | √ |
| 75 | Chlorogenic acida | 354.311 | 9 | 6 | −0.453 |
|
| 76 | Tanshinone IIA | 294.350 | 3 | 0 | 4.158 | √ |
| 77 | Angelicide | 380.48 | 4 | 0 | 5.73 |
|
| 78 | Carthamidin | 288.255 | 6 | 4 | 1.649 | √ |
| 79 | Linoleic acid | 280.45 | 2 | 1 | 6.86 |
|
| 80 | Acetyl-11-keto- | 512.73 | 5 | 1 | 6.39 |
|
| 81 | Oleanolic acid | 456.71 | 3 | 2 | 6.72 |
|
Note. “√” means that component could be absorbed; “✕” means that component could not be absorbed.
“a” refers to the component has been verified by standard substance.
Figure 2Structures of 63 absorbable components.
Top 40 Biocarta pathways regulated by NXT (P < 0.01).
| Rank | Pathway | Count |
|
| Gene |
|---|---|---|---|---|---|
| 1 | NFAT and hypertrophy of the heart (transcription in the broken heart) | 6 | 5.75 | 3.58 | HRAS; GSK3B; MAPK14; FKBP1A; F2; MAP2K1 |
| 2 | Phosphoinositides and their downstream targets | 5 | 1.39 | 8.47 | GSK3B; PDPK1; BTK; RAB5A; EEA1 |
| 3 | Intrinsic Prothrombin Activation Pathway | 4 | 8.50 | 2.82 | F10; FGG; F11; F2 |
| 4 | Bioactive Peptide Induced Signaling Pathway | 4 | 4.08 | 9.30 | HRAS; MAPK14; F2; MAP2K1 |
| 5 | BCR Signaling Pathway | 4 | 4.88 | 1.08 | HRAS; MAPK14; BTK; MAP2K1 |
| 6 | Estrogen-responsive protein Efp controls cell cycle and breast tumors growth | 3 | 6.40 | 1.34 | CDK2; ESR1; CDK6 |
| 7 | Nuclear receptors in lipid metabolism and toxicity | 4 | 8.02 | 1.58 | CYP2C9; VDR; NR1H3; PPARA |
| 8 | Map kinase inactivation of SMRT corepressor | 3 | 1.53 | 2.48 | THRB; MAPK14; MAP2K1 |
| 9 | MAP Kinase Signaling Pathway | 5 | 2.09 | 3.05 | HRAS; MAPK10; MAPK14; TGFBR1; MAP2K1 |
| 10 | Extrinsic Prothrombin Activation Pathway | 3 | 2.99 | 4.05 | F10; FGG; F2 |
| 11 | amiPathway | 3 | 5.17 | 6.40 | F10; FGG; F2 |
| 12 | Roles of | 3 | 6.57 | 7.86 | HRAS; HCK; MAP2K1 |
| 13 | Aspirin blocks signaling pathway involved in platelet activation | 3 | 8.19 | 9.49 | HRAS; F2; MAP2K1 |
| 14 | Insulin Signaling Pathway | 3 | 2.03 | 2.03 | HRAS; INSR; MAP2K1 |
| 15 | IL-2 Signaling Pathway | 3 | 2.37 | 2.29 | HRAS; MAP2K1; LCK |
| 16 | Role of ERBB2 in signal transduction and oncology | 3 | 2.37 | 2.29 | HRAS; ESR1; MAP2K1 |
| 17 | Links between Pyk2 and MAP kinases | 3 | 2.74 | 2.45 | HRAS; MAPK14; MAP2K1 |
| 18 | NF- | 3 | 2.74 | 2.45 | MAPK14; TGFBR1; NR3C1 |
| 19 | Influence of Ras and Rho proteins on G1 to S transition | 3 | 3.14 | 2.82 | HRAS; CDK2; CDK6 |
| 20 | fMLP induced chemokine gene expression in HMC-1 cells | 3 | 3.14 | 2.82 | HRAS; MAPK14; MAP2K1 |
| 21 | Growth Hormone Signaling Pathway | 3 | 3.14 | 2.82 | HRAS; INSR; MAP2K1 |
| 22 | Cell cycle: G1/S checkpoint | 3 | 4.06 | 3.37 | CDK2; GSK3B; CDK6 |
| 23 | Fc epsilon receptor I signaling in mast cells | 3 | 4.58 | 3.70 | HRAS; BTK; MAP2K1 |
| 24 | Signaling of hepatocyte growth factor receptor | 3 | 6.40 | 4.89 | HRAS; MET; MAP2K1 |
| 25 | p38 MAPK signaling pathway | 3 | 7.85 | 5.76 | HRAS; MAPK14; TGFBR1 |
| 26 | Keratinocyte differentiation | 3 | 1.13 | 7.81 | HRAS; MAPK14; MAP2K1 |
| 27 | T cell receptor signaling pathway | 3 | 1.13 | 7.81 | HRAS; MAP2K1; LCK |
| 28 | TSP-1 induced apoptosis in microvascular endothelial cell | 2 | 1.46 | 9.59 | CASP3; MAPK14 |
| 29 | The role of FYVE-finger proteins in vesicle transport | 2 | 1.46 | 9.59 | RAB5A; EEA1 |
| 30 | Mechanism of gene regulation by peroxisome proliferators via PPARa(alpha) | 3 | 1.82 | 1.15 | HSP90AA1; NR1H3; PPARA |
| 31 | Visceral fat deposits and the metabolic syndrome | 2 | 1.95 | 1.21 | HSD11B1; NR3C1 |
| 32 | RB tumor suppressor/checkpoint signaling in response to DNA damage | 2 | 2.50 | 1.44 | CDK2; CHEK1 |
| 33 | Platelet Amyloid Precursor Protein Pathway | 2 | 2.50 | 1.44 | F11; F2 |
| 34 | Fibrinolysis Pathway | 2 | 3.12 | 1.77 | FGG; F2 |
| 35 | Corticosteroids and cardioprotection | 2 | 3.12 | 1.77 | HSP90AA1; NR3C1 |
| 36 | Phosphorylation of MEK1 by cdk5/p35 downregulates the MAP kinase pathway | 2 | 3.81 | 2.09 | HRAS; MAP2K1 |
| 37 | VEGF, hypoxia, and angiogenesis | 2 | 5.38 | 2.79 | HRAS; KDR |
| 38 | How progesterone initiates oocyte membrane | 2 | 6.27 | 3.17 | HRAS; PGR |
| 39 | IL-3 Signaling Pathway | 2 | 6.27 | 3.17 | HRAS; MAP2K1 |
| 40 | Sprouty regulation of tyrosine kinase signals | 2 | 6.27 | 3.17 | HRAS; MAP2K1 |
The herbs of NXT involved in the top 40 pathways.
| Category | Pathway | NXT | RA | RPR | RSM | RAS | RCX | SP | FC | CS | RAB | RC | RM | PT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pathway associated with heart diseases and blood vessels | NFAT and hypertrophy of the heart (transcription in the broken heart) | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Intrinsic Prothrombin Activation Pathway | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | |
| Extrinsic Prothrombin Activation Pathway | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Aspirin blocks signaling pathway involved in platelet activation | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |
| TSP-1 induced apoptosis in microvascular endothelial cell | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Platelet Amyloid Precursor Protein Pathway | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | |
| Fibrinolysis Pathway | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | |
| Corticosteroids and cardioprotection | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | |
| VEGF, hypoxia, and angiogenesis | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
|
| ||||||||||||||
| Pathway associated with metabolism | Nuclear receptors in lipid metabolism and toxicity | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 |
| Growth Hormone Signaling Pathway | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Visceral fat deposits and the metabolic syndrome | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
|
| ||||||||||||||
| Pathway associated with immunity |
| 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| IL-2 Signaling Pathway | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |
| fMLP induced chemokine gene expression in HMC-1 cells | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |
| T Cell Receptor Signaling Pathway | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |
|
| ||||||||||||||
| Pathway associated with cell cycle, proliferation, and apoptosis | Phosphoinositides and their downstream targets | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Estrogen-responsive protein Efp controls cell cycle and breast tumors growth | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |
| Map kinase inactivation of SMRT corepressor | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| MAP Kinase Signaling Pathway | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Roles of | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Role of ERBB2 in signal transduction and oncology | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Links between Pyk2 and MAP kinases | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |
| NF- | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Influence of Ras and Rho proteins on G1 to S transition | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Cell cycle: G1/S checkpoint | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |
| Fc epsilon receptor I signaling in mast cells | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Signaling of hepatocyte growth factor receptor | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Keratinocyte differentiation | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |
| RB tumor Suppressor/checkpoint signaling in response to DNA damage | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |
| IL-3 Signaling Pathway | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Sprouty regulation of tyrosine kinase signals | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |
|
| ||||||||||||||
| Other pathways | Bioactive Peptide Induced Signaling Pathway | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| amiPathway | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Insulin Signaling Pathway | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |
| p38 MAPK Signaling Pathway | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |
| The role of FYVE-finger proteins in vesicle transport | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Mechanism of gene regulation by peroxisome proliferators via PPAR | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | |
| Phosphorylation of MEK1 by cdk5/p35 downregulates the MAP kinase pathway | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |
| How progesterone initiates oocyte membrane | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
Note. “1” means that the Chinese herbal medicine acts on the pathway while “0” means it does not. The pathways in each category are sorted by the significant differences in P value.
Figure 3Pharmacology network of the “components-targets-pathways” regulated by NXT.
Figure 4Network of major targets of NXT with corresponding compounds.